Latest News

DMT prescribing in Canada – Part 2

 

Read Part 1

Detection and diagnosis
Treatment initiation
Untreated patients

Most Canadian patients with multiple sclerosis learn they may have MS from their family doctor or other healthcare professional rather than a neurologist, according to the results of a recent survey. From February to May 2025, Lind Publishing conducted twin surveys of MS healthcare professionals on NeuroSens and of MS patients on its sister website MSology (www.msology.com). There were 64 responses to the HCP survey and 66 responses to the patient survey. Read More

TOPICS:

DMT prescribing in Canada – survey results

 

Read Part 2

Part 1

A majority of patients with multiple sclerosis in Canada are advised to start treatment with a disease-modifying therapy, most commonly with an anti-CD20 treatment, according to the results of a recent survey on NeuroSens. The survey was conducted from 27 February-31 March 2025 and received 64 responses from MS neurologists and nurses. Read More

TOPICS:

CLINICAL CASES IN MS: A 42 Y.O. WOMAN WITH A SEVERE RELAPSE ON DMF

 

Click here to complete the interactive survey.
Once you submit your responses, you will be able to view all of your colleagues’ responses.

J.T. is a 42-year-old woman previously well except for frequent urinary tract infections, which included an episode of pyelonephritis with no known anatomical abnormality. She initially presented with two relapses about six months apart, a mild optic neuritis and a mild sensory myelopathy with excellent spontaneous recovery. Her EDSS score was 1.0.  She was started on dimethyl fumarate. Read More